Sign In
Buy KNSA
$47.85
+0.93 (+1.98%)
At Close: Jun 03, 2026
HAMILTON, Bermuda, June 08, 2020 -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and.
Kiniksa Pharmaceuticals to Present at 41st Annual Goldman Sachs Global Healthcare Conference
12:00pm, Thursday, 04'th Jun 2020
HAMILTON, Bermuda, June 04, 2020 -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 41st Annual Goldman Sachs Global Healthcare.
HAMILTON, Bermuda, May 29, 2020 -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and.
How Kiniksa Pharmaceuticals (KNSA) Stock Stands Out in a Strong Industry
12:56pm, Friday, 22'nd May 2020
Kiniksa Pharmaceuticals (KNSA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and BofA Securities acted as joint book-running managers for the public offering. Wedbush Securities Inc. and JMP Securities LLC acted as co-manage
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering
03:12am, Thursday, 14'th May 2020
The gross proceeds to Kiniksa from this offering, together with the proceeds from the sale of 1,600,000 Class A1 common shares at the public offering price in a concurrent private placement, before fe
Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering
09:12pm, Wednesday, 13'th May 2020
In addition, Kiniksa expects to grant the underwriters a 30-day option to purchase up to 270,000 additional Class A common shares. All of the Class A common shares are being offered by Kiniksa. Kini
– Mavrilimumab treatment protocol in patients with severe COVID-19 pneumonia and hyperinflammation showed improved clinical outcomes compared to matched contemporaneous.
Will Kiniksa Pharmaceuticals Continue to Surge Higher?
03:43pm, Wednesday, 06'th May 2020
As of late, it has definitely been a great time to be an investor Kiniksa Pharmaceuticals
Wedbush Analysts Lift Earnings Estimates for Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA)
06:52am, Saturday, 02'nd May 2020
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) – Analysts at Wedbush raised their Q2 2020 EPS estimates for Kiniksa Pharmaceuticals in a research report issued to clients and investors on Wednesday, Apri
New Strong Buy Stocks for May 1st
01:33pm, Friday, 01'st May 2020
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Wedbush Comments on Kiniksa Pharmaceuticals Ltd's FY2024 Earnings (NASDAQ:KNSA)
09:36am, Friday, 01'st May 2020
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) – Investment analysts at Wedbush issued their FY2024 earnings per share (EPS) estimates for shares of Kiniksa Pharmaceuticals in a note issued to investors
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) Short Interest Update
06:24am, Friday, 01'st May 2020
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 2,260,000 shares, a growth of 19.6% fro
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Reaches New 1-Year High on Earnings Beat
05:50am, Thursday, 30'th Apr 2020
Shares of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) hit a new 52-week high on Wednesday after the company announced better than expected quarterly earnings. The company traded as high as $22.32 and la
The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda
12:40pm, Wednesday, 29'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 28.) * AstraZeneca plc (NYSE: AZN) * Arcturus Therapeu
